An interesting observation here:
From the poster presentation at 2022 MDA Clinical & Scientific Conference
ATL1102 treatment in non-ambulant boys with DMD modulates plasma proteins with roles in TGF-beta mediated fibrosis, and cartilage andbone physiology
ATL1102 increases of BMP5 and BMP6, ligands of the TGF-beta superfamily of proteins, with a role in cartilage and bone formation, suggest a potential for improved bone density. Serum BMP6 levels are reportedly associated with improved elbow flexion in DMD patients.
Bone Morphogenetic Proteins (BMP)
BMP5 - Performs functions in cartilage development.
BMP6 - is the key regulator of hepcidin, the small peptide secreted by the liver which is the major regulator of iron metabolism in mammals.
Both proteins are important regulators of bone homeostasis...
Question: Is there any possibility that ATL1102 can play an important role in future treatment of bone regeneration?
Note: Global Bone and Joint Regenerative Medicines Market $16.9 Billion by 2027
Ann: Poster Presentation at 2022 MDA Conference, page-68
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |